Jan 28, 2021 at 6:15AM
Investing in companies enjoying long-term industry tailwinds can prove to be an extremely profitable strategy -- and both
Regeneron Pharmaceuticals (NASDAQ:REGN) seem to fit that description. While Roku is capitalizing on the shift of customers from cable TV to streaming, Regeneron's COVID-19 therapeutic should also prove to be a solid growth driver in coming months.
So far this year, shares of Roku are up more than 18% while shares of Regeneron Pharmaceuticals have tacked on more than 12%. With Roku positioned as the market-leading streaming video platform and Regeneron Pharmaceuticals making major strides in immunology and oncology, I think that both are poised for a solid growth in 2021.